Laboratory for Anti-Geric Testing, Evaluation and Research

抗感冒测试、评估与研究实验室

• 批准号: 9063022
• 负责人: RICHARD A MILLER
• 金额: $ 148.19万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-01 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9063022
• 关键词: Acarbose; Adult; Age; Aging; Aging-Related Process; Aspirin; Collaborations; Communities; Data; Data Set; Databases; Development; Disease; Dose; Drug effect disorder; Elderly; Estradiol; Evaluation Research; Extensive Stage; Health; Health Sciences; Histopathology; Human; Intervention; Investigation; Joints; Laboratories; Lead; Life; Link; Longevity; Measures; Mediating; Meta-Analysis; Michigan; Mus; Pathology; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Physiological; Policies; Preventive Medicine; Protocols documentation; Reading; Reproducibility; Research; Scientist; Sirolimus; Site; Staging; Statistical Data Interpretation; Structure; System; Testing; Texas; The Jackson Laboratory; Tissue Sample; Tissues; Translational Research; Universities; Work; data management; design; improved; insight; interest; middle age; mouse model; programs; research study; response; sex; trait; web site

DESCRIPTION (provided by applicant): The NIA Interventions Testing Program represents a multi-site translational research program to evaluate agents hypothesized to extend mouse lifespan by retardation of aging or postponement of late life diseases. Interventions proposed by multiple collaborating scientists from the research community are initially tested, in parallel, at three sites (Jackson Laboratories, Michigan and Texas), using identical, standardized protocols, and using sufficient numbers of genetically heterogeneous mice to provide 80% power for detecting changes in lifespan of 10%, for either sex, after pooling data from any two of the test sites. Forty such lifespan experiments, involving various doses of 25 distinct agents, have been initiated in the first nine years of the ITP. Significant effects on longevity, in one or both sexe, have been documented for 5 of the tested agents: aspirin, NDGA, rapamycin, Acarbose, and 17-�-estradiol. Initial lifespan trials are now underway for 8 agents, as well as comprehensive analyses of the effects of rapamycin, Acarbose, and NDGA on health and on cellular and physiological traits thought likely to mediate the beneficial effects seen. Plans for the next five year period include additional lifespan ("Stage I") trials, detailed analyses ("Stage II") of agent found to increase lifespan, and some increased emphasis on collaborations with other scientists skilled at evaluating traits related to health and disease or at testing ideas about mechanisms of drug action on aging. Each of the three ITP laboratories will bring special expertise to the effort measures of age-sensitive traits at the Jackson Laboratory, pathology and statistical analysis at Michigan, and pharmacology at the University of Texas.

描述（由申请方提供）：NIA干预试验项目代表了一项多中心转化研究项目，旨在评价假设可通过延缓衰老或延缓晚期疾病来延长小鼠寿命的药物。由来自研究界的多位合作科学家提出的干预措施最初在 三个地点（杰克逊实验室，密歇根州和得克萨斯州），使用相同的标准化方案，并使用足够数量的遗传异质性小鼠，以提供80%的功效，用于在合并来自任何两个测试地点的数据后检测10%的寿命变化。在ITP的前九年，已经启动了40个这样的寿命实验，涉及25种不同药剂的不同剂量。在一种或两种性别中，有5种测试药物对长寿有显著影响：阿司匹林、NDGA、雷帕霉素、阿卡波糖和17-β-雌二醇。目前正在进行8种药物的初步寿命试验，以及对雷帕霉素、阿卡波糖和NDGA对健康以及被认为可能介导所见有益效果的细胞和生理特征的影响的全面分析。未来五年的计划 在为期一年的时间里，研究人员进行了一些研究，包括额外的寿命（“第一阶段”）试验，对发现可延长寿命的药物进行详细分析（“第二阶段”），以及更加重视与其他科学家的合作，这些科学家擅长评估与健康和疾病有关的特征，或测试有关药物对衰老作用机制的想法。三个ITP实验室中的每一个都将为杰克逊实验室的年龄敏感性状、密歇根州的病理学和统计分析以及德克萨斯大学的药理学的努力措施带来特殊的专业知识。